The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission

• Published in: PLoS neglected tropical diseases 2018-11, Vol.12 (11), p.e0006809-e0006809
• Main Authors: Bartsch, Sarah M, Avelis, Cameron M, Asti, Lindsey, Hertenstein, Daniel L, Ndeffo-Mbah, Martial, Galvani, Alison, Lee, Bruce Y
• Format: Article
• Language: English
• Subjects: Access; Animals; Antiprotozoal Agents - economics; Antiprotozoal Agents - therapeutic use; Biology and Life Sciences; Blood & organ donations; Causes of; Chagas disease; Chagas Disease - drug therapy; Chagas Disease - economics; Chagas Disease - parasitology; Chagas Disease - transmission; Congenital diseases; Cost analysis; Cost benefit analysis; Disease prevention; Disease transmission; Dogs; Econometric models; Economic analysis; Economic aspects; Economic models; Economics; Health care access; Humans; Identification; Impact analysis; Infections; Infectious diseases; Medical treatment; Medicine and Health Sciences; Mexico; Mortality; Obesity; Operations research; Organizations; Patients; People and places; Physiological aspects; Population; Prevention; Protozoa; Public health; Retirement benefits; Secondary Prevention - economics; Social Sciences; Studies; Transmission; Treatment Outcome; Tropical diseases; Trypanosoma cruzi; Trypanosoma cruzi - drug effects; Trypanosoma cruzi - physiology; Vector-borne diseases; Vectors (Biology); Veterinary medicine
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0006809

The World Health Organization's 2020 Goals for Chagas disease include access to antiparasitic treatment and care of all infected/ill patients. Policy makers need to know the economic value of identifying and treating patients earlier. However, the economic value of earlier treatment to cure and prevent the Chagas' spread remains unknown. We expanded our existing Chagas disease transmission model to include identification and treatment of Chagas disease patients. We linked this to a clinical and economic model that translated chronic Chagas disease cases into health and economic outcomes. We evaluated the impact and economic outcomes (costs, cost-effectiveness, cost-benefit) of identifying and treating different percentages of patients in the acute and indeterminate disease states in a 2,000-person village in Yucatan, Mexico. In the absence of early treatment, 50 acute and 22 new chronic cases occurred over 50 years. Identifying and treating patients in the acute stage averted 0.5-5.4 acute cases, 0.6-5.5 chronic cases, and 0.6-10.8 disability-adjusted life years (DALYs), saving $694-$7,419 and $6,976-$79,950 from the third-party payer and societal perspectives, respectively. Treating in the indeterminate stage averted 2.2-4.9 acute cases, 6.1-12.8 chronic cases, and 11.7-31.1 DALYs, saving $7,666-$21,938 from the third-party payer perspective and $90,530-$243,068 from the societal perspective. Treating patients in both stages averted ≤9 acute cases and ≤15 chronic cases. Identifying and treating patients early was always economically dominant compared to no treatment. Identifying and treating patients earlier resulted in a cumulative cost-benefit of $7,273-$224,981 at the current cost of identification and treatment. Even when identifying and treating as little as 5% of cases annually, treating Chagas cases in the acute and indeterminate stages reduces transmission and provides economic and health benefits. This supports the need for improved diagnostics and access to safe and effective treatment.